Trial Profile
A Phase 1-2 Trial of MM-121 in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 11 Aug 2020
Price :
$35
*
At a glance
- Drugs Seribantumab (Primary) ; Erlotinib
- Indications Adenocarcinoma; Brain metastases; Carcinoma; HER2 negative breast cancer; Non-small cell lung cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Merrimack Pharmaceuticals
- 26 Sep 2018 Results presented at the 19th World Conference on Lung Cancer
- 12 Jul 2016 Status changed from active, no longer recruiting to completed.
- 18 May 2016 Results from this and 2 other trials were presented at the AACR Precision Medicine Series, according to a Merrimack Pharmaceuticals media release.